Biological
mRNA COVID-19 Vaccine clinical trials
- studies test it
- 18
- open now
- 3
- in phase 3
- 5
- first study started
- 2021
Keep track of what changes. Save the mRNA COVID-19 Vaccine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
18 studies that test it; most in 2021 (7)
| Year | Studies |
|---|---|
| 2021 | 7 |
| 2022 | 3 |
| 2023 | 4 |
| 2024 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 7
- Phase 3
- 5
- Phase 4
- 2
What it is tested for
Each study’s main condition, where its own words name it.
- COVID-19
- 10
Who runs them
Industry 12 · Other 6
Duke University (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · CanSino Biologics Inc. (2) · CNBG-Virogin Biotech (Shanghai) Ltd. (2) · Invivyd, Inc. (1) · GlaxoSmithKline (1) · Sanofi Pasteur, a Sanofi Company (1) · Vaccine Company, Inc. (1)
Often tested with
Tested in the same studies.
Ibramvibart (1) · Tacrolimus (1) · Arexvy (1) · 2019-nCoV Vaccine mRNA-1273 (1) · VXCO-100 (1) · Influenza Vaccines (1)
Studies
Open first, then newest update. How each study uses mRNA COVID-19 Vaccine is read from its arms, and is right about nine times in ten.
Testing it · 18
- Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.RecruitingPhase 1/2ANRS, Emerging Infectious DiseasesNCT06255626Written as CD40.RBDv vaccin (SARS-Cov2 Vaccin)
- A PhaseⅡ Study to Evaluate the Safety and Immunogenicity of COVID-19 VaccineRecruitingPhase 2CNBG-Virogin Biotech (Shanghai) Ltd.NCT06113731Written as COVID-19 mRNA Vaccine (ZSVG-02-O)
- A Phase 1 Study to Evaluate the Safety and Immunogenicity of COVID-19 VaccineRecruitingPhase 1CNBG-Virogin Biotech (Shanghai) Ltd.NCT06113744Written as COVID-19 mRNA Vaccine (ZSVG-02-O) 10 μg
- Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 VaccineCompletedPhase 3Invivyd, Inc.NCT07655180Written as COVID-19 mRNA vaccine
- Simultaneous mRNA COVID-19 and IIV Vaccination in Pregnancy StudyCompletedPhase 4Duke UniversityNCT06503900Written as mRNA COVID-19 vaccine
- Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young ChildrenCompletedPhase 4Duke UniversityNCT06038617Written as mRNA COVID-19 Vaccine
- COVID Protection After Transplant-Immunosuppression ReductionCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT05077254Written as Pfizer-BioNTech COVID-19 Vaccine 2023-2024
- A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and AboveCompletedPhase 3GlaxoSmithKlineNCT06374394Written as COVID-19 mRNA vaccine
- Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 VaccineCompletedPhase 2Sanofi Pasteur, a Sanofi CompanyNCT04969276Written as COVID-19 mRNA Vaccine (nucleoside modified)
- COVID-19 Protection After Transplant Pilot StudyCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT04969263Written as BNT162b2 vaccine (Pfizer/BioNTech)
- Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South AfricaCompletedPhase 1Vaccine Company, Inc.NCT05938075Written as COVID-19 mRNA vaccine
- Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and OlderCompletedPhase 2CanSino Biologics Inc.NCT05373472Written as COVID-19 mRNA vaccine
- Phase I Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and OlderCompletedPhase 1CanSino Biologics Inc.NCT05373485Written as COVID-19 mRNA vaccine
- Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Vaccine BoosterCompletedPhase 1Argorna Pharmaceuticals Co., LTDNCT05897190Written as SARS-CoV-2 mRNA vaccine (RBMRNA-405)
- A Phase I/II Clinical Trial in Healthy People Aged 18 Years and AboveCompletedPhase 1/2Stemirna TherapeuticsNCT05144139Written as COVID-19 mRNA vaccine
- Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo)Status unknownPhase 3University of LiegeNCT04951323Written as anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)
- A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and AboveStatus unknownPhase 3Walvax Biotechnology Co., Ltd.NCT04847102Written as SARS-CoV-2 mRNA Vaccine
- COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and OlderWithdrawnPhase 3BayerNCT04848467Written as SARS-CoV-2 mRNA Vaccine (CVnCoV)
Given in every arm · 1 — mRNA COVID-19 Vaccine is usual care beside what is tested
As the comparator · 4 — what is tested is compared with mRNA COVID-19 Vaccine
- A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic LeukemiaCompletedPhase 2City of Hope Medical CenterNCT05672355Written as mRNA COVID-19 Vaccine
- Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated AdultsActive, not recruitingPhase 2CastleVax Inc.NCT07215520Written as COVID-19 mRNA Vaccine
- Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a BoosterWithdrawnPhase 2WestVac Biopharma Co., Ltd.NCT05465902Written as mRNA COVID-19 vaccine (Moderna)
- A Study to Evaluate the Safety and Immunogenicity of Ad5-vector Based Vaccine Against Coronavirus Variants in Adults (≥18 Years) Immunized With 2 Doses of mRNA Vaccines Plus One Dose of Booster AZD1222 VaccineWithdrawnPhase 3CanSino Biologics Inc.NCT05442684Written as mRNA-based COVID-19 vaccine